Market Overview

UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT

Related NKTR
Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting
Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

In a report published Monday, Jefferies & Company downgraded its rating on Nektar Therapeutics (NASDAQ: NKTR) from Buy to Hold, and lowered its price target from $10.00 to $8.00.

Jefferies noted, “We are downgrading NKTR to Hold from Buy with a new $8 PT based on increased regulatory risks in OIC. Recent FDA scrutiny on CV risks with chronic µ-opioid antagonist use translates to higher approval hurdles potentially involving add'l large CV outcome studies and potentially delaying naloxegol's approval/launch. Thus, NKTR is fairly valued on increased risks.”

Nektar Therapeutics closed on Friday at $8.15.

Latest Ratings for NKTR

DateFirmActionFromTo
Sep 2014Bank of AmericaMaintainsUnderperform
Sep 2014Brean CapitalMaintainsBuy
Jun 2014Ladenburg ThalmannInitiates Coverage onBuy

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (NKTR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters